News & Events about Fusion Pharmaceuticals Inc.
TipRanks Financial Blog
3 months ago
JonesTrading analyst Justin Walsh maintained a Buy rating on Fusion Pharmaceuticals (FUSN Research Report) today and set a price target of $12.00... JonesTrading analyst Justin Walsh maintained a Buy rating on Fusion Pharmaceuticals (FUSN Resear...
Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R PR Newswire HAMILTON, ON and BOSTON, June 26...
CNW Group - News Releases
3 months ago
Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R Canada NewsWire HAMILTON, ON and BOSTON, June...
Raymond Jameshas initiated coverage onFusion Pharmaceuticals Inc(NASDAQ: FUSN) with an Outperform rating and a
Latest Ratings for FUSN
DateFirmActionFromTo Aug 2021B. Riley SecuritiesInitiates Coverage OnBuy Aug 2021Morgan StanleyMaintainsOverweight May 2021Morgan StanleyMaintainsOverweight
View...
CNW Group - News Releases
3 months ago
Fusion Pharmaceuticals to Present at the TD Cowen Radiopharmaceutical Innovation Summit Fusion Pharmaceuticals to Present at the TD Cowen Radiopharmaceutical Innovation Summit Canada NewsWire HAMILTON, ON and BOSTON, June 16, 2023 HAMILTON, ON and BOSTON, June 16, 2023 /CNW/ -- Fusion...